Implications of COVID-19 Outbreak on Immune Therapies in Multiple Sclerosis Patients-Lessons Learned From SARS and MERS.

Front Immunol · 2020 · PMC7235419 · PMID 32477373

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

Fingolimod and natalizumab showed a trend toward an increased rate of infection compared with interferon beta and glatiramer acetate, but no significance was found ( 3 ).

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.